Portola Pharmaceuticals, Inc. Reports Second Quarter Financial Results and Provides Corporate Update

Published: Aug 15, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) today will provide a corporate update and report its financial results for the quarter ended June 30, 2013.

“In the second quarter, we completed a successful IPO, raising approximately $126 million in net proceeds, which will allow us to develop our two late-stage thrombosis programs and a dual Syk-JAK inhibitor for hematologic cancers,” said William Lis, chief executive officer of Portola.

Hey, check out all the research scientist jobs. Post your resume today!

Back to news